{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:18:18Z","timestamp":1783117098446,"version":"3.54.6"},"reference-count":96,"publisher":"Aging and Disease","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging and disease"],"published-print":{"date-parts":[[2024]]},"DOI":"10.14336\/ad.2024.0434","type":"journal-article","created":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T21:50:58Z","timestamp":1719179458000},"page":"0","source":"Crossref","is-referenced-by-count":6,"title":["Dysregulation of Lipid Metabolism Serves as A Link Between Alzheimer\u2019s and Cardiovascular Disease, As Witnessed in A Cross-Sectional Study"],"prefix":"10.14336","author":[{"given":"Laura","family":"Mourino-Alvarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Juarez-Alia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Sastre-Oliva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Perales-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Hernandez-Fernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Chicano-Galvez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Peralbo-Molina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Madruga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Blanco-Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Tejerina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda G.","family":"Barderas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5462","reference":[{"key":"key-10.14336\/AD.2024.0434-1","doi-asserted-by":"crossref","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch\u00e9telat G, Teunissen CE, et al. (2021). Alzheimer's disease. Lancet, 397:1577-1590.","DOI":"10.1016\/S0140-6736(20)32205-4"},{"key":"key-10.14336\/AD.2024.0434-2","doi-asserted-by":"crossref","unstructured":"Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. (2017). Dementia prevention, intervention, and care. Lancet, 390:2673-2734.","DOI":"10.1016\/S0140-6736(17)31363-6"},{"key":"key-10.14336\/AD.2024.0434-3","doi-asserted-by":"crossref","unstructured":"Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet, 396:413-446.","DOI":"10.1016\/S0140-6736(20)30367-6"},{"key":"key-10.14336\/AD.2024.0434-4","doi-asserted-by":"crossref","unstructured":"Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C (2014). Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol, 13:788-794.","DOI":"10.1016\/S1474-4422(14)70136-X"},{"key":"key-10.14336\/AD.2024.0434-5","doi-asserted-by":"crossref","unstructured":"van Nieuwkerk AC, Delewi R, Wolters FJ, Muller M, Daemen M, Biessels GJ (2023). Cognitive Impairment in Patients With Cardiac Disease: Implications for Clinical Practice. Stroke, 54:2181-2191.","DOI":"10.1161\/STROKEAHA.123.040499"},{"key":"key-10.14336\/AD.2024.0434-6","doi-asserted-by":"crossref","unstructured":"de Bruijn RF, Ikram MA (2014). Cardiovascular risk factors and future risk of Alzheimer's disease. BMC Med, 12:130.","DOI":"10.1186\/s12916-014-0130-5"},{"key":"key-10.14336\/AD.2024.0434-7","doi-asserted-by":"crossref","unstructured":"Kwok CS, Loke YK, Hale R, Potter JF, Myint PK (2011). Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology, 76:914-922.","DOI":"10.1212\/WNL.0b013e31820f2e38"},{"key":"key-10.14336\/AD.2024.0434-8","doi-asserted-by":"crossref","unstructured":"Dublin S, Anderson ML, Heckbert SR, Hubbard RA, Sonnen JA, Crane PK, et al. (2014). Neuropathologic changes associated with atrial fibrillation in a population-based autopsy cohort. J Gerontol A Biol Sci Med Sci, 69:609-615.","DOI":"10.1093\/gerona\/glt141"},{"key":"key-10.14336\/AD.2024.0434-9","doi-asserted-by":"crossref","unstructured":"Knecht S, Oelschl\u00e4ger C, Duning T, Lohmann H, Albers J, Stehling C, et al. (2008). Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J, 29:2125-2132.","DOI":"10.1093\/eurheartj\/ehn341"},{"key":"key-10.14336\/AD.2024.0434-10","doi-asserted-by":"crossref","unstructured":"Ovsenik A, Podbregar M, Fabjan A (2021). Cerebral blood flow impairment and cognitive decline in heart failure. Brain Behav, 11:e02176.","DOI":"10.1002\/brb3.2176"},{"key":"key-10.14336\/AD.2024.0434-11","doi-asserted-by":"crossref","unstructured":"Stamatelopoulos K, Sibbing D, Rallidis LS, Georgiopoulos G, Stakos D, Braun S, et al. (2015). Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease. J Am Coll Cardiol, 65:904-916.","DOI":"10.1016\/j.jacc.2014.12.035"},{"key":"key-10.14336\/AD.2024.0434-12","doi-asserted-by":"crossref","unstructured":"Stamatelopoulos K, Pol CJ, Ayers C, Georgiopoulos G, Gatsiou A, Brilakis ES, et al. (2018). Amyloid-Beta (1-40) Peptide and Subclinical Cardiovascular Disease. J Am Coll Cardiol, 72:1060-1061.","DOI":"10.1016\/j.jacc.2018.06.027"},{"key":"key-10.14336\/AD.2024.0434-13","doi-asserted-by":"crossref","unstructured":"Cortes-Canteli M, Iadecola C (2020). Alzheimer's Disease and Vascular Aging: JACC Focus Seminar. J Am Coll Cardiol, 75:942-951.","DOI":"10.1016\/j.jacc.2019.10.062"},{"key":"key-10.14336\/AD.2024.0434-14","doi-asserted-by":"crossref","unstructured":"Juul Rasmussen I, Frikke-Schmidt R (2023). Modifiable cardiovascular risk factors and genetics for targeted prevention of dementia. Eur Heart J, 44:2526-2543.","DOI":"10.1093\/eurheartj\/ehad293"},{"key":"key-10.14336\/AD.2024.0434-15","doi-asserted-by":"crossref","unstructured":"Teunissen CE, Veerhuis R, De Vente J, Verhey FR, Vreeling F, van Boxtel MP, et al. (2011). Brain-specific fatty acid-binding protein is elevated in serum of patients with dementia-related diseases. Eur J Neurol, 18:865-871.","DOI":"10.1111\/j.1468-1331.2010.03273.x"},{"key":"key-10.14336\/AD.2024.0434-16","doi-asserted-by":"crossref","unstructured":"Chen Y, Strickland MR, Soranno A, Holtzman DM (2021). Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis. Neuron, 109:205-221.","DOI":"10.1016\/j.neuron.2020.10.008"},{"key":"key-10.14336\/AD.2024.0434-17","doi-asserted-by":"crossref","unstructured":"Jiang Y, Zhu Z, Shi J, An Y, Zhang K, Wang Y, et al. (2019). Metabolomics in the Development and Progression of Dementia: A Systematic Review. Front Neurosci, 13:343.","DOI":"10.3389\/fnins.2019.00343"},{"key":"key-10.14336\/AD.2024.0434-18","doi-asserted-by":"crossref","unstructured":"Ore\u0161i\u010d M, Hy\u00f6tyl\u00e4inen T, Herukka SK, Sysi-Aho M, Mattila I, Sepp\u00e4nan-Laakso T, et al. (2011). Metabolome in progression to Alzheimer's disease. Transl Psychiatry, 1:e57.","DOI":"10.1038\/tp.2011.55"},{"key":"key-10.14336\/AD.2024.0434-19","doi-asserted-by":"crossref","unstructured":"Sweeney MD, Montagne A, Sagare AP, Nation DA, Schneider LS, Chui HC, et al. (2019). Vascular dysfunction-The disregarded partner of Alzheimer's disease. Alzheimers Dement, 15:158-167.","DOI":"10.1016\/j.jalz.2019.06.2792"},{"key":"key-10.14336\/AD.2024.0434-20","doi-asserted-by":"crossref","unstructured":"Pang Z, Chong J, Zhou G, de Lima Morais DA, Chang L, Barrette M, et al. (2021). MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Res, 49:W388-w396.","DOI":"10.1093\/nar\/gkab382"},{"key":"key-10.14336\/AD.2024.0434-21","doi-asserted-by":"crossref","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. (2023). The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res, 51:D638-d646.","DOI":"10.1093\/nar\/gkac1000"},{"key":"key-10.14336\/AD.2024.0434-22","doi-asserted-by":"crossref","unstructured":"Zhou G, Pang Z, Lu Y, Ewald J, Xia J (2022). OmicsNet 2.0: a web-based platform for multi-omics integration and network visual analytics. Nucleic Acids Res, 50:W527-w533.","DOI":"10.1093\/nar\/gkac376"},{"key":"key-10.14336\/AD.2024.0434-23","doi-asserted-by":"crossref","unstructured":"Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011). Alzheimer's disease. Lancet, 377:1019-1031.","DOI":"10.1016\/S0140-6736(10)61349-9"},{"key":"key-10.14336\/AD.2024.0434-24","doi-asserted-by":"crossref","unstructured":"de la Torre JC (2010). Vascular risk factor detection and control may prevent Alzheimer's disease. Ageing Res Rev, 9:218-225.","DOI":"10.1016\/j.arr.2010.04.002"},{"key":"key-10.14336\/AD.2024.0434-25","doi-asserted-by":"crossref","unstructured":"Xue-Shan Z, Juan P, Qi W, Zhong R, Li-Hong P, Zhi-Han T, et al. (2016). Imbalanced cholesterol metabolism in Alzheimer's disease. Clin Chim Acta, 456:107-114.","DOI":"10.1016\/j.cca.2016.02.024"},{"key":"key-10.14336\/AD.2024.0434-26","doi-asserted-by":"crossref","unstructured":"Akyol O, Akyol S, Chou MC, Chen S, Liu CK, Selek S, et al. (2023). Lipids and lipoproteins may play a role in the neuropathology of Alzheimer's disease. Front Neurosci, 17:1275932.","DOI":"10.3389\/fnins.2023.1275932"},{"key":"key-10.14336\/AD.2024.0434-27","doi-asserted-by":"crossref","unstructured":"Hadjiphilippou S, Ray KK (2018). Lipids and Lipoproteins in Risk Prediction. Cardiol Clin, 36:213-220.","DOI":"10.1016\/j.ccl.2017.12.002"},{"key":"key-10.14336\/AD.2024.0434-28","doi-asserted-by":"crossref","unstructured":"Kawakita E, Hashimoto M, Shido O (2006). Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience, 139:991-997.","DOI":"10.1016\/j.neuroscience.2006.01.021"},{"key":"key-10.14336\/AD.2024.0434-29","doi-asserted-by":"crossref","unstructured":"Latifi S, Tamayol A, Habibey R, Sabzevari R, Kahn C, Geny D, et al. (2016). Natural lecithin promotes neural network complexity and activity. Sci Rep, 6:25777.","DOI":"10.1038\/srep25777"},{"key":"key-10.14336\/AD.2024.0434-30","doi-asserted-by":"crossref","unstructured":"Hasan M, Latifi S, Kahn CJF, Tamayol A, Habibey R, Passeri E, et al. (2018). The Positive Role of Curcumin-Loaded Salmon Nanoliposomes on the Culture of Primary Cortical Neurons. Mar Drugs, 16.","DOI":"10.3390\/md16070218"},{"key":"key-10.14336\/AD.2024.0434-31","doi-asserted-by":"crossref","unstructured":"Malaplate C, Poerio A, Huguet M, Soligot C, Passeri E, Kahn CJF, et al. (2019). Neurotrophic Effect of Fish-Lecithin Based Nanoliposomes on Cortical Neurons. Mar Drugs, 17.","DOI":"10.3390\/md17070406"},{"key":"key-10.14336\/AD.2024.0434-32","doi-asserted-by":"crossref","unstructured":"Milos T, Rojo D, Nedic Erjavec G, Konjevod M, Tudor L, Vuic B, et al. (2023). Metabolic profiling of Alzheimer's disease: Untargeted metabolomics analysis of plasma samples. Prog Neuropsychopharmacol Biol Psychiatry, 127:110830.","DOI":"10.1016\/j.pnpbp.2023.110830"},{"key":"key-10.14336\/AD.2024.0434-33","doi-asserted-by":"crossref","unstructured":"Desale SE, Chinnathambi S (2020). Role of dietary fatty acids in microglial polarization in Alzheimer's disease. J Neuroinflammation, 17:93.","DOI":"10.1186\/s12974-020-01742-3"},{"key":"key-10.14336\/AD.2024.0434-34","doi-asserted-by":"crossref","unstructured":"de Souza CO, Valenzuela CA, Baker EJ, Miles EA, Rosa Neto JC, Calder PC (2018). Palmitoleic Acid has Stronger Anti-Inflammatory Potential in Human Endothelial Cells Compared to Oleic and Palmitic Acids. Mol Nutr Food Res, 62:e1800322.","DOI":"10.1002\/mnfr.201800322"},{"key":"key-10.14336\/AD.2024.0434-35","doi-asserted-by":"crossref","unstructured":"de Souza CO, Vannice GK, Rosa Neto JC, Calder PC (2018). Is Palmitoleic Acid a Plausible Nonpharmacological Strategy to Prevent or Control Chronic Metabolic and Inflammatory Disorders? Mol Nutr Food Res, 62.","DOI":"10.1002\/mnfr.201700504"},{"key":"key-10.14336\/AD.2024.0434-36","doi-asserted-by":"crossref","unstructured":"Berm\u00fadez MA, Pereira L, Fraile C, Valerio L, Balboa MA, Balsinde J (2022). Roles of Palmitoleic Acid and Its Positional Isomers, Hypogeic and Sapienic Acids, in Inflammation, Metabolic Diseases and Cancer. Cells, 11.","DOI":"10.3390\/cells11142146"},{"key":"key-10.14336\/AD.2024.0434-37","doi-asserted-by":"crossref","unstructured":"Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. (2018). Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77\u202f917 Individuals. JAMA Cardiol, 3:225-234.","DOI":"10.1001\/jamacardio.2017.5205"},{"key":"key-10.14336\/AD.2024.0434-38","doi-asserted-by":"crossref","unstructured":"Tortosa-Caparr\u00f3s E, Navas-Carrillo D, Mar\u00edn F, Orenes-Pi\u00f1ero E (2017). Anti-inflammatory effects of omega 3 and omega 6 polyunsaturated fatty acids in cardiovascular disease and metabolic syndrome. Crit Rev Food Sci Nutr, 57:3421-3429.","DOI":"10.1080\/10408398.2015.1126549"},{"key":"key-10.14336\/AD.2024.0434-39","doi-asserted-by":"crossref","unstructured":"Pan A, Chen M, Chowdhury R, Wu JH, Sun Q, Campos H, et al. (2012). \u03b1-Linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr, 96:1262-1273.","DOI":"10.3945\/ajcn.112.044040"},{"key":"key-10.14336\/AD.2024.0434-40","doi-asserted-by":"crossref","unstructured":"Das UN (2010). Essential fatty acids and their metabolites in the context of hypertension. Hypertens Res, 33:782-785.","DOI":"10.1038\/hr.2010.105"},{"key":"key-10.14336\/AD.2024.0434-41","doi-asserted-by":"crossref","unstructured":"Qi K, Fan C, Jiang J, Zhu H, Jiao H, Meng Q, et al. (2008). Omega-3 fatty acid containing diets decrease plasma triglyceride concentrations in mice by reducing endogenous triglyceride synthesis and enhancing the blood clearance of triglyceride-rich particles. Clin Nutr, 27:424-430.","DOI":"10.1016\/j.clnu.2008.02.001"},{"key":"key-10.14336\/AD.2024.0434-42","doi-asserted-by":"crossref","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. (2019). Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med, 380:11-22.","DOI":"10.1056\/NEJMoa1812792"},{"key":"key-10.14336\/AD.2024.0434-43","doi-asserted-by":"crossref","unstructured":"Honda KL, Lamon-Fava S, Matthan NR, Wu D, Lichtenstein AH (2015). Docosahexaenoic acid differentially affects TNF\u03b1 and IL-6 expression in LPS-stimulated RAW 264.7 murine macrophages. Prostaglandins Leukot Essent Fatty Acids, 97:27-34.","DOI":"10.1016\/j.plefa.2015.03.002"},{"key":"key-10.14336\/AD.2024.0434-44","doi-asserted-by":"crossref","unstructured":"Wang Z, Guo A, Ma L, Yu H, Zhang L, Meng H, et al. (2016). Docosahexenoic acid treatment ameliorates cartilage degeneration via a p38 MAPK-dependent mechanism. Int J Mol Med, 37:1542-1550.","DOI":"10.3892\/ijmm.2016.2567"},{"key":"key-10.14336\/AD.2024.0434-45","doi-asserted-by":"crossref","unstructured":"Shramko VS, Polonskaya YV, Kashtanova EV, Stakhneva EM, Ragino YI (2020). The Short Overview on the Relevance of Fatty Acids for Human Cardiovascular Disorders. Biomolecules, 10.","DOI":"10.3390\/biom10081127"},{"key":"key-10.14336\/AD.2024.0434-46","doi-asserted-by":"crossref","unstructured":"Tallima H, El Ridi R (2018). Arachidonic acid: Physiological roles and potential health benefits - A review. J Adv Res, 11:33-41.","DOI":"10.1016\/j.jare.2017.11.004"},{"key":"key-10.14336\/AD.2024.0434-47","doi-asserted-by":"crossref","unstructured":"Kawanabe A, Okamura Y (2016). Effects of unsaturated fatty acids on the kinetics of voltage-gated proton channels heterologously expressed in cultured cells. J Physiol, 594:595-610.","DOI":"10.1113\/JP271274"},{"key":"key-10.14336\/AD.2024.0434-48","doi-asserted-by":"crossref","unstructured":"Giudetti AM, Stanca E, Siculella L, Gnoni GV, Damiano F (2016). Nutritional and Hormonal Regulation of Citrate and Carnitine\/Acylcarnitine Transporters: Two Mitochondrial Carriers Involved in Fatty Acid Metabolism. Int J Mol Sci, 17.","DOI":"10.3390\/ijms17060817"},{"key":"key-10.14336\/AD.2024.0434-49","doi-asserted-by":"crossref","unstructured":"Cao B, Wang D, Pan Z, Brietzke E, McIntyre RS, Musial N, et al. (2019). Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study. Transl Psychiatry, 9:19.","DOI":"10.1038\/s41398-018-0353-x"},{"key":"key-10.14336\/AD.2024.0434-50","doi-asserted-by":"crossref","unstructured":"Horgusluoglu E, Neff R, Song WM, Wang M, Wang Q, Arnold M, et al. (2022). Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease. Alzheimers Dement, 18:1260-1278.","DOI":"10.1002\/alz.12468"},{"key":"key-10.14336\/AD.2024.0434-51","doi-asserted-by":"crossref","unstructured":"Cristofano A, Sapere N, La Marca G, Angiolillo A, Vitale M, Corbi G, et al. (2016). Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimer's Dementia. PLoS One, 11:e0155694.","DOI":"10.1371\/journal.pone.0155694"},{"key":"key-10.14336\/AD.2024.0434-52","doi-asserted-by":"crossref","unstructured":"Toledo JB, Arnold M, Kastenm\u00fcller G, Chang R, Baillie RA, Han X, et al. (2017). Metabolic network failures in Alzheimer's disease: A biochemical road map. Alzheimers Dement, 13:965-984.","DOI":"10.1016\/j.jalz.2017.01.020"},{"key":"key-10.14336\/AD.2024.0434-53","doi-asserted-by":"crossref","unstructured":"Gao F, Kovalik JP, Zhao X, Chow VJ, Chew H, Teo LL, et al. (2021). Exacerbation of cardiovascular ageing by diabetes mellitus and its associations with acyl-carnitines. Aging (Albany NY), 13:14785-14805.","DOI":"10.18632\/aging.203144"},{"key":"key-10.14336\/AD.2024.0434-54","doi-asserted-by":"crossref","unstructured":"Shah SH, Bain JR, Muehlbauer MJ, Stevens RD, Crosslin DR, Haynes C, et al. (2010). Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet, 3:207-214.","DOI":"10.1161\/CIRCGENETICS.109.852814"},{"key":"key-10.14336\/AD.2024.0434-55","doi-asserted-by":"crossref","unstructured":"Akwa Y (2020). Steroids and Alzheimer's Disease: Changes Associated with Pathology and Therapeutic Potential. Int J Mol Sci, 21.","DOI":"10.3390\/ijms21134812"},{"key":"key-10.14336\/AD.2024.0434-56","doi-asserted-by":"crossref","unstructured":"Shufelt C, Bretsky P, Almeida CM, Johnson BD, Shaw LJ, Azziz R, et al. (2010). DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health--National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab, 95:4985-4992.","DOI":"10.1210\/jc.2010-0143"},{"key":"key-10.14336\/AD.2024.0434-57","doi-asserted-by":"crossref","unstructured":"Thijs L, Fagard R, Forette F, Nawrot T, Staessen JA (2003). Are low dehydroepiandrosterone sulphate levels predictive for cardiovascular diseases? A review of prospective and retrospective studies. Acta Cardiol, 58:403-410.","DOI":"10.2143\/AC.58.5.2005304"},{"key":"key-10.14336\/AD.2024.0434-58","doi-asserted-by":"crossref","unstructured":"Page JH, Ma J, Rexrode KM, Rifai N, Manson JE, Hankinson SE (2008). Plasma dehydroepiandrosterone and risk of myocardial infarction in women. Clin Chem, 54:1190-1196.","DOI":"10.1373\/clinchem.2007.099291"},{"key":"key-10.14336\/AD.2024.0434-59","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez MC, Sun Q, Sch\u00fcrks M, Chiuve S, Hu FB, Manson JE, et al. (2013). Low dehydroepiandrosterone sulfate is associated with increased risk of ischemic stroke among women. Stroke, 44:1784-1789.","DOI":"10.1161\/STROKEAHA.111.000485"},{"key":"key-10.14336\/AD.2024.0434-60","doi-asserted-by":"crossref","unstructured":"Baloni P, Funk CC, Yan J, Yurkovich JT, Kueider-Paisley A, Nho K, et al. (2020). Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and Metabolism in Alzheimer's Disease. Cell Rep Med, 1:100138.","DOI":"10.2139\/ssrn.3596216"},{"key":"key-10.14336\/AD.2024.0434-61","doi-asserted-by":"crossref","unstructured":"MahmoudianDehkordi S, Arnold M, Nho K, Ahmad S, Jia W, Xie G, et al. (2019). Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome. Alzheimers Dement, 15:76-92.","DOI":"10.1016\/j.jalz.2019.03.002"},{"key":"key-10.14336\/AD.2024.0434-62","doi-asserted-by":"crossref","unstructured":"Nho K, Kueider-Paisley A, MahmoudianDehkordi S, Arnold M, Risacher SL, Louie G, et al. (2019). Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. Alzheimers Dement, 15:232-244.","DOI":"10.1016\/j.jalz.2018.08.012"},{"key":"key-10.14336\/AD.2024.0434-63","doi-asserted-by":"crossref","unstructured":"McMillin M, DeMorrow S (2016). Effects of bile acids on neurological function and disease. Faseb j, 30:3658-3668.","DOI":"10.1096\/fj.201600275R"},{"key":"key-10.14336\/AD.2024.0434-64","doi-asserted-by":"crossref","unstructured":"Bazzari FH, Abdallah DM, El-Abhar HS (2019). Chenodeoxycholic Acid Ameliorates AlCl(3)-Induced Alzheimer's Disease Neurotoxicity and Cognitive Deterioration via Enhanced Insulin Signaling in Rats. Molecules, 24.","DOI":"10.3390\/molecules24101992"},{"key":"key-10.14336\/AD.2024.0434-65","doi-asserted-by":"crossref","unstructured":"Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B (2009). Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev, 89:147-191.","DOI":"10.1152\/physrev.00010.2008"},{"key":"key-10.14336\/AD.2024.0434-66","doi-asserted-by":"crossref","unstructured":"Bishop-Bailey D, Walsh DT, Warner TD (2004). Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci U S A, 101:3668-3673.","DOI":"10.1073\/pnas.0400046101"},{"key":"key-10.14336\/AD.2024.0434-67","doi-asserted-by":"crossref","unstructured":"Swales KE, Moore R, Truss NJ, Tucker A, Warner TD, Negishi M, et al. (2012). Pregnane X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress. Cardiovasc Res, 93:674-681.","DOI":"10.1093\/cvr\/cvr330"},{"key":"key-10.14336\/AD.2024.0434-68","doi-asserted-by":"crossref","unstructured":"Huang F, Mariani N, Pariante CM, Borsini A (2023). From dried bear bile to molecular investigation of differential effects of bile acids in ex vivo and in vitro models of myocardial dysfunction: Relevance for neuroinflammation. Brain Behav Immun Health, 32:100674.","DOI":"10.1016\/j.bbih.2023.100674"},{"key":"key-10.14336\/AD.2024.0434-69","doi-asserted-by":"crossref","unstructured":"Khurana S, Raufman JP, Pallone TL (2011). Bile acids regulate cardiovascular function. Clin Transl Sci, 4:210-218.","DOI":"10.1111\/j.1752-8062.2011.00272.x"},{"key":"key-10.14336\/AD.2024.0434-70","doi-asserted-by":"crossref","unstructured":"Desai MS, Penny DJ (2013). Bile acids induce arrhythmias: old metabolite, new tricks. Heart, 99:1629-1630.","DOI":"10.1136\/heartjnl-2013-304546"},{"key":"key-10.14336\/AD.2024.0434-71","doi-asserted-by":"crossref","unstructured":"Oeckl P, Otto M (2019). A Review on MS-Based Blood Biomarkers for Alzheimer's Disease. Neurol Ther, 8:113-127.","DOI":"10.1007\/s40120-019-00165-4"},{"key":"key-10.14336\/AD.2024.0434-72","doi-asserted-by":"crossref","unstructured":"Gonzalez-Riano C, Garcia A, Barbas C (2016). Metabolomics studies in brain tissue: A review. J Pharm Biomed Anal, 130:141-168.","DOI":"10.1016\/j.jpba.2016.07.008"},{"key":"key-10.14336\/AD.2024.0434-73","doi-asserted-by":"crossref","unstructured":"Bernath MM, Bhattacharyya S, Nho K, Barupal DK, Fiehn O, Baillie R, et al. (2020). Serum triglycerides in Alzheimer disease: Relation to neuroimaging and CSF biomarkers. Neurology, 94:e2088-e2098.","DOI":"10.1212\/WNL.0000000000009436"},{"key":"key-10.14336\/AD.2024.0434-74","doi-asserted-by":"crossref","unstructured":"Reddan JM, White DJ, Macpherson H, Scholey A, Pipingas A (2018). Glycerophospholipid Supplementation as a Potential Intervention for Supporting Cerebral Structure in Older Adults. Front Aging Neurosci, 10:49.","DOI":"10.3389\/fnagi.2018.00049"},{"key":"key-10.14336\/AD.2024.0434-75","doi-asserted-by":"crossref","unstructured":"Tomczyk MM, Dolinsky VW (2020). The Cardiac Lipidome in Models of Cardiovascular Disease. Metabolites, 10.","DOI":"10.3390\/metabo10060254"},{"key":"key-10.14336\/AD.2024.0434-76","doi-asserted-by":"crossref","unstructured":"O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. (2010). Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet, 376:112-123.","DOI":"10.1016\/S0140-6736(10)60834-3"},{"key":"key-10.14336\/AD.2024.0434-77","doi-asserted-by":"crossref","unstructured":"Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. (2020). Modifiable risk factors, cardiovascular disease, and mortality in 155\u2008722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet, 395:795-808.","DOI":"10.1016\/S0140-6736(19)32008-2"},{"key":"key-10.14336\/AD.2024.0434-78","unstructured":"Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. (2013). Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet, 45:1345-1352."},{"key":"key-10.14336\/AD.2024.0434-79","doi-asserted-by":"crossref","unstructured":"Fernandez C, Sandin M, Sampaio JL, Almgren P, Narkiewicz K, Hoffmann M, et al. (2013). Plasma lipid composition and risk of developing cardiovascular disease. PLoS One, 8:e71846.","DOI":"10.1371\/journal.pone.0071846"},{"key":"key-10.14336\/AD.2024.0434-80","doi-asserted-by":"crossref","unstructured":"Stegemann C, Pechlaner R, Willeit P, Langley SR, Mangino M, Mayr U, et al. (2014). Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation, 129:1821-1831.","DOI":"10.1161\/CIRCULATIONAHA.113.002500"},{"key":"key-10.14336\/AD.2024.0434-81","doi-asserted-by":"crossref","unstructured":"Razquin C, Liang L, Toledo E, Clish CB, Ruiz-Canela M, Zheng Y, et al. (2018). Plasma lipidome patterns associated with cardiovascular risk in the PREDIMED trial: A case-cohort study. Int J Cardiol, 253:126-132.","DOI":"10.1016\/j.ijcard.2017.10.026"},{"key":"key-10.14336\/AD.2024.0434-82","doi-asserted-by":"crossref","unstructured":"Dean M, Hamon Y, Chimini G (2001). The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res, 42:1007-1017.","DOI":"10.1016\/S0022-2275(20)31588-1"},{"key":"key-10.14336\/AD.2024.0434-83","doi-asserted-by":"crossref","unstructured":"Chen L, Zhao ZW, Zeng PH, Zhou YJ, Yin WJ (2022). Molecular mechanisms for ABCA1-mediated cholesterol efflux. Cell Cycle, 21:1121-1139.","DOI":"10.1080\/15384101.2022.2042777"},{"key":"key-10.14336\/AD.2024.0434-84","doi-asserted-by":"crossref","unstructured":"Lewandowski CT, Laham MS, Thatcher GRJ (2022). Remembering your A, B, C's: Alzheimer's disease and ABCA1. Acta Pharm Sin B, 12:995-1018.","DOI":"10.1016\/j.apsb.2022.01.011"},{"key":"key-10.14336\/AD.2024.0434-85","doi-asserted-by":"crossref","unstructured":"Choi HY, Choi S, Iatan I, Ruel I, Genest J (2023). Biomedical Advances in ABCA1 Transporter: From Bench to Bedside. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020561"},{"key":"key-10.14336\/AD.2024.0434-86","doi-asserted-by":"crossref","unstructured":"Liu CG, Zhao Y, Lu Y, Wang PC (2021). ABCA1-Labeled Exosomes in Serum Contain Higher MicroRNA-193b Levels in Alzheimer's Disease. Biomed Res Int, 2021:5450397.","DOI":"10.1155\/2021\/5450397"},{"key":"key-10.14336\/AD.2024.0434-87","doi-asserted-by":"crossref","unstructured":"Li Y, Meng S, Di W, Xia M, Dong L, Zhao Y, et al. (2022). Amyloid-\u03b2 protein and MicroRNA-384 in NCAM-Labeled exosomes from peripheral blood are potential diagnostic markers for Alzheimer's disease. CNS Neurosci Ther, 28:1093-1107.","DOI":"10.1111\/cns.13846"},{"key":"key-10.14336\/AD.2024.0434-88","doi-asserted-by":"crossref","unstructured":"Mather KA, Thalamuthu A, Oldmeadow C, Song F, Armstrong NJ, Poljak A, et al. (2016). Genome-wide significant results identified for plasma apolipoprotein H levels in middle-aged and older adults. Sci Rep, 6:23675.","DOI":"10.1038\/srep23675"},{"key":"key-10.14336\/AD.2024.0434-89","doi-asserted-by":"crossref","unstructured":"Sodin-Semrl S, Rozman B (2007). Beta2-glycoprotein I and its clinical significance: from gene sequence to protein levels. Autoimmun Rev, 6:547-552.","DOI":"10.1016\/j.autrev.2007.02.002"},{"key":"key-10.14336\/AD.2024.0434-90","doi-asserted-by":"crossref","unstructured":"Castro A, L\u00e1zaro I, Selva DM, C\u00e9spedes E, Girona J, N\u00fariaPlana, et al. (2010). APOH is increased in the plasma and liver of type 2 diabetic patients with metabolic syndrome. Atherosclerosis, 209:201-205.","DOI":"10.1016\/j.atherosclerosis.2009.09.072"},{"key":"key-10.14336\/AD.2024.0434-91","doi-asserted-by":"crossref","unstructured":"Miyakis S, Giannakopoulos B, Krilis SA (2004). Beta 2 glycoprotein I--function in health and disease. Thromb Res, 114:335-346.","DOI":"10.1016\/j.thromres.2004.07.017"},{"key":"key-10.14336\/AD.2024.0434-92","doi-asserted-by":"crossref","unstructured":"Leduc MS, Shimmin LC, Klos KL, Hanis C, Boerwinkle E, Hixson JE (2008). Comprehensive evaluation of apolipoprotein H gene (APOH) variation identifies novel associations with measures of lipid metabolism in GENOA. J Lipid Res, 49:2648-2656.","DOI":"10.1194\/jlr.M800155-JLR200"},{"key":"key-10.14336\/AD.2024.0434-93","doi-asserted-by":"crossref","unstructured":"Muenchhoff J, Poljak A, Song F, Raftery M, Brodaty H, Duncan M, et al. (2015). Plasma protein profiling of mild cognitive impairment and Alzheimer's disease across two independent cohorts. J Alzheimers Dis, 43:1355-1373.","DOI":"10.3233\/JAD-141266"},{"key":"key-10.14336\/AD.2024.0434-94","doi-asserted-by":"crossref","unstructured":"George J, Afek A, Gilburd B, Blank M, Levy Y, Aron-Maor A, et al. (1998). Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation, 98:1108-1115.","DOI":"10.1161\/01.CIR.98.11.1108"},{"key":"key-10.14336\/AD.2024.0434-95","doi-asserted-by":"crossref","unstructured":"McDonnell T, Wincup C, Buchholz I, Pericleous C, Giles I, Ripoll V, et al. (2020). The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. Blood Rev, 39:100610.","DOI":"10.1016\/j.blre.2019.100610"},{"key":"key-10.14336\/AD.2024.0434-96","doi-asserted-by":"crossref","unstructured":"Liu Y, Zhao Y, Liu Q, Li B, Daniel PV, Chen B, et al. (2024). Effects of apolipoprotein H downregulation on lipid metabolism, fatty liver disease, and gut microbiota dysbiosis. J Lipid Res, 65:100483.","DOI":"10.1016\/j.jlr.2023.100483"}],"container-title":["Aging and disease"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T21:51:32Z","timestamp":1719179492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aginganddisease.org\/EN\/10.14336\/AD.2024.0434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":96,"URL":"https:\/\/doi.org\/10.14336\/ad.2024.0434","relation":{},"ISSN":["2152-5250"],"issn-type":[{"value":"2152-5250","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}